Linaclotide

What is Linaclotide?

Linaclotide is a 14-amino-acid oral peptide that activates guanylate cyclase-C (GC-C) receptors on the luminal side of intestinal epithelial cells. It is FDA-approved for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults, and since 2023 for functional constipation in children aged 6–17. Unlike most peptide therapeutics, linaclotide is taken orally as a capsule: it is designed to survive gastric transit, act locally on intestinal GC-C, and be essentially unabsorbed — drug concentrations in systemic circulation are below quantification in healthy volunteers. It is marketed as Linzess in the US (AbbVie/Ironwood) and Constella in Europe and other markets.

What Linaclotide Is Investigated For

Linaclotide is one of the best-evidenced oral peptide drugs on the market. The strongest data are in IBS-C — the 26-week Chey/Lembo pivotal trial (n=804) showed 33.7% FDA-endpoint responders on 290 mcg once-daily versus 13.9% on placebo — and in chronic idiopathic constipation, where two 12-week pivotal trials in 1,276 adults (Lembo 2011, NEJM) established the 145 mcg and 290 mcg doses. A lower 72 mcg dose was validated for CIC in a 1,223-patient trial (Brenner 2018), giving clinicians three approved strengths for titration. The 2023 pediatric approval for functional constipation (ages 6–17) rested on a 328-patient Phase 3 trial using 72 mcg once-daily. Abdominal pain reduction — not just bowel-habit change — is a distinctive linaclotide signal, mediated by GC-C/cGMP activity on submucosal visceral afferents. The honest caveats are narrow but important. Linaclotide is contraindicated in children under 6 because of a dose-dependent mortality signal from dehydration in juvenile mice; the pediatric label carries this warning, and off-label use in toddlers is genuinely dangerous. Diarrhea is the defining dose-limiting side effect, causing 4–6% of patients to discontinue. The drug has no established role in non-constipating GI conditions, and its essentially local-only pharmacology means it is not a general 'gut health' agent.

History & Discovery

Linaclotide's intellectual lineage begins not in a drug-discovery program but in microbiology. Guanylate cyclase-C (GC-C) was characterized in the 1980s and 1990s as the intestinal receptor for E. coli heat-stable enterotoxin (STa), the peptide toxin responsible for a major share of traveler's diarrhea and childhood diarrheal disease worldwide. STa binds GC-C, triggers intracellular cGMP, and drives the massive intestinal fluid secretion that causes the diarrheal illness. Parallel work identified the endogenous mammalian ligands of the same receptor — guanylin and uroguanylin — small cysteine-rich peptides secreted by intestinal enterocytes that regulate normal fluid homeostasis. Microbia Inc., founded in Cambridge, Massachusetts in the early 2000s, set out to exploit this biology therapeutically: if STa could pathologically overstimulate GC-C to produce diarrhea, a carefully tuned synthetic analog might therapeutically stimulate GC-C to produce controlled laxation and the relief of constipation. The company designed linaclotide (then MD-1100) as a 14-amino-acid peptide with three disulfide bonds, engineered for oral stability through gastric transit and for local action on GC-C in the small and large intestine. Microbia rebranded as Ironwood Pharmaceuticals in 2008 and advanced linaclotide through Phase II (Johnston 2010, Gastroenterology) into the pivotal Phase III program. The Phase III package was unusually clean for a GI indication. Two 12-week CIC trials in 1,276 adults (Lembo 2011, NEJM) established 145 mcg and 290 mcg as effective doses for chronic idiopathic constipation. The IBS-C program — the 26-week Chey 2012 trial (n=804) and the 12-week Rao 2012 trial with randomized withdrawal (n=800) — established 290 mcg for IBS-C, with a distinguishing signal on abdominal pain that was traced mechanistically to GC-C-dependent effects on visceral afferents (Eutamene/Bueno 2010, Neurogastroenterol Motil). The FDA approved Linzess in August 2012, with US commercialization jointly by Ironwood and Forest Laboratories (later acquired by Actavis, then Allergan, then AbbVie). European approval followed as Constella. Label expansion continued over the next decade. A 72 mcg dose was added for CIC in 2017 on the basis of Brenner et al.'s 1,223-patient Phase 3 trial. In June 2023, the FDA approved linaclotide for functional constipation in children aged 6–17 — the first prescription therapy approved for pediatric functional constipation, supported by the 328-patient Di Lorenzo Phase 3 trial published in Lancet Gastroenterology & Hepatology in 2024. A pediatric IBS-C approval (ages 7 and older) followed based on a separate Phase 3 trial. The drug has become the most prescribed IBS-C and CIC prescription therapy in the US, and the 2022 AGA guideline gave it one of the strongest drug recommendations in the entire IBS-C pharmacologic class.

How It Works

Linaclotide is a tiny peptide that stays in your gut instead of being absorbed. It turns on a molecular switch (GC-C) on the inside surface of the intestine, which tells the gut to pump more water and salt into the bowel. The extra fluid softens stool, speeds up transit, and — uniquely for this drug class — also calms the pain-sensing nerves in the gut wall.

Linaclotide is a 14-amino-acid peptide designed around the natural GC-C ligands guanylin and uroguanylin, with three disulfide bonds stabilizing it against gastric and intestinal proteases. It binds and activates guanylate cyclase-C (GC-C) on the apical (luminal) surface of intestinal epithelial cells, triggering intracellular accumulation of cyclic GMP (cGMP). Elevated cGMP activates protein kinase II, which phosphorylates and opens the cystic fibrosis transmembrane conductance regulator (CFTR), driving secretion of chloride and bicarbonate into the intestinal lumen. Water follows osmotically, increasing luminal fluid and accelerating transit. A second, independently validated mechanism accounts for linaclotide's analgesic effect on abdominal pain. Extracellular cGMP generated by enterocyte GC-C activation reaches submucosal visceral afferent nerve terminals, where it dampens nociceptor excitability. In rodent models of visceral hypersensitivity — TNBS colitis, water-avoidance stress, partial restraint stress — linaclotide reduces abdominal contractions to colorectal distension in wild-type mice but not in GC-C knockouts (Eutamene/Bueno 2010), establishing that the antinociceptive effect is GC-C-dependent rather than a nonspecific bulk-effect consequence of laxation. This dual mechanism — secretory plus antinociceptive — distinguishes GC-C agonists from osmotic laxatives, stimulants, and prokinetics and is the mechanistic basis for linaclotide's abdominal-pain labeling in IBS-C. Linaclotide is essentially unabsorbed. Its GC-C target is expressed almost exclusively on intestinal epithelium in adults, which is why systemic pharmacokinetic interactions are not a meaningful concern. The evolutionary origin of the drug class is notable: GC-C was discovered as the receptor for E. coli heat-stable enterotoxin (STa), which causes traveler's diarrhea. Linaclotide is, in effect, a therapeutically tuned and orally deliverable version of that same biology.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Linaclotide:

• 01Pediatric long-term safety beyond the approved indications and follow-up windows — the 2023 pediatric approval rested on 12-week data; decade-scale developmental, growth, and GI-microbiome outcomes in children treated from age 6 are not yet characterized.
• 02Combination therapy with other IBS-C or CIC agents (plecanatide, tenapanor, lubiprostone, prucalopride) — not formally studied; whether any combination offers additional benefit in refractory patients is an open question.
• 03Role in other GC-C-relevant conditions — GC-C agonism has been explored preclinically for colon cancer prevention, brown fat thermogenesis, and inflammatory bowel disease modulation; linaclotide's clinical utility outside its approved constipation indications is investigational.
• 04Real-world long-term (multi-year to decade) effectiveness — randomized data extend to 26 weeks; observational cohorts are now accumulating multi-year follow-up, but adherence patterns, discontinuation reasons, and effectiveness attenuation over years are still being characterized.
• 05Dose individualization for tolerance-vs-efficacy optimization — the approved doses are set by indication, but real-world clinicians frequently titrate off-label (stepping down 290 mcg to 145 mcg or 72 mcg for tolerability); formal evidence supporting within-indication dose adjustment is limited.
• 06Pregnancy outcomes — registry-level human pregnancy outcomes data is limited; the essentially-unabsorbed pharmacology suggests low fetal risk, but formal characterization is ongoing.

Forms & Administration

Oral capsule, 72 mcg / 145 mcg / 290 mcg strengths. Once daily, taken on an empty stomach at least 30 minutes before the first meal of the day. Capsules can be opened and sprinkled on applesauce or in bottled water for patients with difficulty swallowing, following the specific label instructions for each strength. Linaclotide is a prescription-only specialty product and is not legitimately available outside of pharmacy distribution.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Linaclotide is contraindicated in pediatric patients under 6 years of age due to a dose-dependent mortality signal in juvenile mice (dehydration from intestinal fluid secretion). Off-label use in toddlers and infants is specifically warned against. Approved pediatric use is limited to ages 6+ for functional constipation and ages 7+ for IBS-C.

Timeline of Effects

Common Questions

Who Linaclotide Is NOT For

Drug & Supplement Interactions

Linaclotide's defining pharmacokinetic feature — that it is essentially unabsorbed, with plasma concentrations below the limit of quantification at therapeutic doses — makes classical drug-drug interactions through CYP-mediated metabolism, plasma protein binding, or renal clearance a non-issue. Linaclotide does not meaningfully inhibit or induce CYP enzymes, and is not a clinically relevant substrate of common drug transporters. The more realistic interaction domain is pharmacodynamic and gut-based. Concurrent use of other laxatives (osmotic agents like polyethylene glycol, stimulants like senna, or other secretagogues) can additively increase stool frequency and diarrhea risk; this is manageable but should be explicit rather than inadvertent. Concurrent use of loperamide or anticholinergic agents may partially blunt linaclotide's effect. In patients with accelerated transit from linaclotide, the absorption kinetics of narrow-therapeutic-index oral medications (warfarin, levothyroxine, some anticonvulsants) could theoretically be altered, though systematic PK interaction studies have not demonstrated clinically important changes in most cases. Linaclotide should be taken on an empty stomach at least 30 minutes before the first meal of the day. Administration with food — particularly a high-fat meal — increases looser stools and diarrhea rates without improving efficacy, and is explicitly discouraged in labeling. This food-timing effect is the closest thing to a clinically relevant 'interaction' for most patients.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions